Idarubicine
Autologous Hematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical UniversityPhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Autologous Hematopoietic Stem Cell Transplantation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CARVEDILOL Hospital Clinic of Barcelona | Phase 3 | BB |
Busulphan Nanfang Hospital, Southern Medical University | Phase 2/3 | B |
Cyclophosphamide Nanfang Hospital, Southern Medical University | Phase 2/3 | B |
Enalapril Hospital Clinic of Barcelona | Phase 3 | B |
Evomela Nanfang Hospital, Southern Medical University | Phase 2/3 | B |
View all 10 →
Same molecule, other indications
Idarubicine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →